Synonyms: h-R3 | THERACIM® | Theraloc®
nimotuzumab is an approved drug (China, India, others (2014))
Compound class:
Antibody
Comment: Nimotuzumab is a monoclonal antibody directed agianst the epidermal growth factor receptor (EGFR), being developed as an antineoplastic agent.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. Peptide sequence analysis using the light chain variable region of nimotuzumab provides a 100% match with sequence 35 from patent US6506883 [1]. Biosimilar drug: Biocon Limited are developing BIOMAb-EGFRTM as a nimotuzumab biosimilar |
Classification | |
Compound class | Antibody |
Approved drug? | Yes (China, India, others (2014)) |
International Nonproprietary Names | |
INN number | INN |
8545 | nimotuzumab |
Synonyms |
h-R3 | THERACIM® | Theraloc® |
Database Links | |
Specialist databases | |
IMGT/mAb-DB | 76 |
Other databases | |
GtoPdb PubChem SID | 249565669 |
Search PubMed clinical trials | nimotuzumab |
Search PubMed titles | nimotuzumab |
Search PubMed titles/abstracts | nimotuzumab |
Wikipedia | Nimotuzumab |